Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia, Hyperplasia, Adrenal Hyperplasia
About this trial
This is an interventional treatment trial for Congenital Adrenal Hyperplasia focused on measuring adrenal gland diseases, cortisol succinate, hydrocortisone, hyperplasia
Eligibility Criteria
Inclusion Criteria:
- Children 4 - 18 years of age.
- Classic congenital adrenal hyperplasia (CAH) as confirmed by hormonal and molecular testing.
- Patients who have been on the same HC dosing regimen for 1 month
Exclusion Criteria:
- Patients with non-classic CAH.
Patients on:
- Dexamethasone
- Prednisone, or
- inhaled steroids.
- Patients with body surface areas under 1m2 or over 2m2
- Non-English speaking patients
Sites / Locations
- Prism Clinical Research
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Subcutaneous Hydrocortisone via Infusion Pump
Standard glucocorticoid therapy
Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
Subjects in this arm will continue on standard oral hydrocortisone therapy